Our favorite posts:
Dr. Fauci: ‘Remdesivir should now be the standard treatment’ and A Moonshot Moment for the Muslims: Making Covid 19 Vaccine before the West and China
Professor Didier Raoult. Suggested reading WHO pauses hydroxychloroquine study due to safety concerns and France bans hydroxychloroquine to treat COVID-19 amid safety concerns
Professor Didier Raoult Releases the Results of a New Hydroxychloroquine Treatment Study on 1061 Patients
For more precise information please read this study from New England Journal of Medicine as well: NEJM study about Plaquenil in Covid 19
The new study, of which the abstract was released today, was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated.
Key findings are:
- No cardiac toxicity was observed.
- A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).
A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more.
The authors conclude that:
“The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.”
See the complete abstract below.
The original abstract can be accessed here.
Also, the researchers made this table available.
It’s not clear when the complete study will be made available.
ABSTRACT
Background
In a recent survey, most physicians worldwide considered that hydroxychloroquine (HCQ) and azithromycin (AZ) are the two most effective drugs among available molecules against COVID-19. Nevertheless, to date, one preliminary clinical trial only has demonstrated its efficacy on the viral load. Additionally, a clinical study including 80 patients was published, and in vitro efficiency of this association was demonstrated.
Methods
The study was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the HCQ-AZ combination and a follow-up of at least 9 days was investigated. Endpoints were death, worsening and viral shedding persistence.
Findings
From March 3rd to April 9th, 2020, 59,655 specimens from 38,617 patients were tested for COVID-19 by PCR. Of the 3,165 positive patients placed in the care of our institute, 1061 previously unpublished patients met our inclusion criteria. Their mean age was 43.6 years old and 492 were male (46.4%). No cardiac toxicity was observed. A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage at completion of treatment was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < 10-2) but viral culture was negative at day 10 and all but one were PCR-cleared at day 15. A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more. Among this group, 25 patients are now cured and 16 are still hospitalized (98% of patients cured so far). Poor clinical outcome was significantly associated to older age (OR 1.11), initial higher severity (OR 10.05) and low hydroxychloroquine serum concentration. In addition, both poor clinical and virological outcomes were associated to the use of selective beta-blocking agents and angiotensin II receptor blockers (P<0.05). Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens both at IHU and in all Marseille public hospitals (p< 10-2).
Dr. Zia H Shah, Chief Editor of the Muslim Times and in charge of health section
The best of the Muslim Times’ collection for war against Covid 19:
Coronavirus: Hydroxychloroquine trial to restart
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
France bans hydroxychloroquine to treat COVID-19 amid safety concerns
Kaiser Permanente launches first coronavirus vaccine trial
Corona Fear’s Cure: Chanting from the Bible and the Quran
Can You Chant from the Bible or the Quran to Bliss and Happiness?
Japanese flu drug ‘clearly effective’ in treating coronavirus, says China
Synthetic antibodies might offer a quick coronavirus treatment
The Four Possible Timelines for Life Returning to Normal
The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic
Coronavirus: TB Vaccination Trial Started in Melbourne, Australia
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
All of humanity are intimate neighbors: Coronavirus proves it once again
Praise be to God for the Miracle of Our Immune System
USA: 15-minute coronavirus test is here
Does the Ordinary Soap Kill Coronavirus?
Here’s a list of disinfectants you can use against coronavirus
For the number of cases and epidemiology in each country go to: WorldOMeters
The Muslim Times has the best collection on the theme of Religion & Science
Categories: Health, The Muslim Times
PARIS—Sporting long white hair, a shaggy beard and a skull ring on his right pinkie finger, a French doctor with a history of challenging the medical establishment has become a folk hero here by stoking the controversy over the use of an antimalarial drug to treat Covid-19.
Didier Raoult, a 68-year-old infectious-disease specialist, has emerged as a standard-bearer for those who support the use of the medicine, hydroxycholoroquine, to treat the growing number of people sickened by the new coronavirus, despite a lack of evidence…
TO READ THE FULL STORY
https://www.wsj.com/articles/french-doctor-leads-charge-for-treating-coronavirus-with-antimalarial-drug-11586629801
His research team has published data showing that out of 80 mild Covid-19 patients treated with hydroxychloroquine and azithromycin, 93 percent had no detectable levels of the virus after eight days.
Dr. Raoult recommends administering the drug at an early stage, before Covid-19 causes serious damage to patients’ lungs.
https://www.wsj.com/articles/french-doctor-leads-charge-for-treating-coronavirus-with-antimalarial-drug-11586629801